#1charles river Meeting with Management Research Models & Services Colin Dunn, Ph.D. Corporate Senior Vice President, Global Research Models & Services September 21, 2023#2Focus Areas of Today's Discussion on RMS Segment Charles River Laboratories (CRL) Accelerated growth • Sustained long-term RMS growth potential through leading position, global scale, and focus on emerging areas of growth • China and CRADL™M China and CRADL™ remain two of the most meaningful growth drivers, as well as opportunities across our broader service offering and in key biohubs Digitally enabled Inventory optimization and e-commerce initiatives are transforming the speed and efficiency of this 75-year-old business 2#3Research Models & Services (RMS) Overview #1 Global RMS Position ◉ - - - Global leader in breeding and distribution of research models -40% CRL Largest selection of the most widely used research model strains in the world Expertise in biosecurity supports production of high-quality models, reducing risk to critical research Sustained by the assurance of animal welfare with 4Rs commitments Global footprint with facilities strategically located in close proximity to clients Premier provider of services that support the use of research models in discovery/development of new molecules Genetically Engineered Models & Services (GEMS) Research Animal Diagnostic Services (RADS) Global RMS Market Sector Size: ~$2B ~1 of 2 Small models sold in Western regions is a CRL research model Insourcing Solutions (IS), including CRADL TM operations Cell Solutions provides research, clinical, and CGMP-quality human-derived cellular products used in allogeneic (donor-derived) and autologous (patient- derived) cell therapies Charles River Laboratories (CRL) 3#41 Key RMS Growth Drivers Current Target: 6%-8% 2023-2026E RMS organic revenue CAGR Drive Insourcing Solutions and CRADL™ growth Expand CRADLTM in additional geographies to ensure regional biohub coverage 4 2 Target growth in biohubs Targeted sales strategies aimed at growing biotech and academic markets Enhance digital enterprise Enhance e-commerce, data personalization, and further digitalization of the client experience 5 3 ulk Continue China expansion Strong growth with ramping up capacity utilization of the research model production footprint and diversifying the range of services, including CRADL™ Growing focus on cell therapy Continue to enhance offering around cell therapy and other advanced therapies Charles River Laboratories (CRL) 4#5Insourcing Solutions and CRADL™ Growth ■ Insourcing Solutions offers clients a variety of flexible solutions - Legacy offering enhances the efficiency of clients' vivarium management CRADL™ offers flexible, turnkey vivarium space at a CRL site supported by our management and technical experts CRADL's™ flexible operational models within our infrastructure are attracting new biopharma clients • • Now have more than >30 locations and >400K ft² in 5 states and 3 countries First location opened in Boston/Cambridge biohub in 2015 Continue to expand into new biohub regions to drive future growth, including CRADL™ in China Plan to open >10 sites over next 5 years Supports flexible growth of entire life sciences ecosystem in each biohub CRADL™ allows clients to invest in their research programs instead of their infrastructure Unique pathway to connect with clients at earlier stages and leverage access to additional CRL services across our comprehensive discovery and non-clinical development portfolio crad charles river accelerator & development lab Charles River Laboratories (CRL) 5#6Targeting Growth in Biohubs Targeted initiatives in key biohubs to capture biotech and academic share gains and growth Targeted Sales Approach Digital Experience Portfolio Expansion Charles River Laboratories (CRL) ☐ ☐ • Agile commercial structure to access clients around academic/biotech lab spinout phase Example: >240 biotechs spun out of 130 academic 'foundation' labs in Massachusetts over last 5 years Enhance pull-through across different business units including Discovery Services, Cell Solutions, and C&GT CDMO Enhanced use of e-commerce to achieve 'persona-centric' digital experiences Drive scientific-rich content and client-centric apps to promote market penetration and exposure of biohub clients across multiple businesses Increased capacity and portfolio expansion in GEMS, CRADL TM, and immunodeficient models to better support this client base, which is more C&GT focused 6#7China RMS Growth Drivers - - CRL China RMS Position ($) RMS China averaged robust, double-digit annual revenue growth since acquired in 2013 Recent expansion focused on R&D hubs central (Wuhan), southern (Shunde), and western (Chengdu) regions Lower, near-term growth expectations for biomedical research in China Downward trend in capital market activity in China began in 2H22 with sharper drop in 2023, which had impacted mid-tier biopharma/CRO demand Small model and services revenue in China expected to continue to grow at a faster rate than the RMS segment target over the longer term Primary drivers towards long-term goal of greater market penetration in China Continued ramp-up of capacity at new sites to assure presence in Tier 1 biohubs Synergies with and expansion of adjacent RMS service lines, including additional CRADLTM and GEMS capacity Adopt enhanced automation and digital optimization initiatives in China 37% CRL 15%+ of RMS revenue RMS China as a % of RMS segment revenue* China is CRL's largest research models region by unit volume Charles River Laboratories (CRL) * China represents only ~4% of total CRL revenue. 7#8Strong Foundation Enables Client-Focused RMS Digital Experience ■ ■ - - Leveraging enhanced digital footprint to transform the client and user experience Focus on elevating operational quality with high data integrity, resilient infrastructure and elimination of manual processes Increased speed by managing projects in one integrated platform for more efficient workflow Provide clients with real-time, 24-hour access to scientific project data, provision of quotes and order confirmations Enabled self-service client capabilities across all areas of RMS portfolio including online ordering for research models Launched RMS e-commerce tools in 2Q23 with >10% of research models orders in North America Almost half of orders processed and confirmed in less than 1 second Rollout underway in Europe Charles River Laboratories (CRL) Personalization Resiliency Quality Digitization Data Connectivity Experience 8#9Cell Therapy Growth Spans the RMS Portfolio - Humanized and super-immunodeficient rodent models are critical for cell therapy development and preclinical safety assessment Many cell therapies are in the area of oncology, e.g. CAR-T therapies Strong presence in the key Cambridge and South San Francisco biohubs offering turnkey CRADLTM vivarium space Attracting a range of biopharma companies – small and large Additional synergies for CRADL TM from growing biotech clients providing new business opportunities in the GEMS business Additional synergies more broadly across CRL portfolio, particularly in DSA Cell Solutions provides materials that are a critical foundation to support cell therapy development process from research through commercialization Illustrates the highly bespoke nature of the in vivo models that clients use in their R&D programs Charles River Laboratories (CRL) 9#10Global RMS Strategic Imperatives Portfolio Expansion Expand scope of entire RMS portfolio through technology partnerships and other alliances Ⓒ Operational Efficiency ■ Gain Share Excel in operational effectiveness with digital investments, automation, and supply chain management Win share and drive market penetration with digitalization, e-commerce, by advancing product mix, and portfolio expansion with a focus on biohubs strategy Innovate to Sustain Innovate to lead and sustain our market position and client reach with a focus on the 4Rs 82 Advance Culture Celebrate our people in their success to develop their skills, build careers, and dedicate to their vocations Charles River Laboratories (CRL) 10#11charles river CRL LISTED NYSE